Alteogen is a leading biopharmaceutical company with a robust pipeline of next-generation biologics featuring enhanced efficacy, enabled by its proprietary platform technologies. Founded in 2008, the company is listed on the KOSDAQ stock exchange (KRX:196170). Alteogen’s most distinguished platform, Hybrozyme™, is a novel human hyaluronidase technology that enhances the absorption of biologic drugs administered via subcutaneous injection. This proprietary hyaluronidase demonstrates improved enzymatic activity and thermal stability compared to existing alternatives. Another key innovation, NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body. It is currently applied to the development of long-acting biologics, including human growth hormone, exenatide (for diabetes), and Factor VIIa (for hemophilia). The company’s proprietary antibody-drug conjugate platform, NexMab™ ADC technology, enables targeted cancer therapies with improved efficacy and reduced side effects. Using this platform, Alteogen is developing ADC therapeutics for breast, gastric, and ovarian cancers. With extensive expertise and experience, Alteogen has also established its own high-expression cell lines, efficient upstream and downstream processes, and optimized analytical methods to support the development of monoclonal antibody biosimilars.
我们正在追踪 ALTEOGEN Inc. 的市场扩张
最近 90 天内有 2 个信号。
ALTEOGEN Inc. 的国际扩张与竞争对手的对比情况
ALTEOGEN Inc.你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 ALTEOGEN Inc.你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
D&D Pharmatech、Alteogen和Peptron股价急升,因D&D准备在EASL会议上发表MASH管线数据。分析师强调即将公布的临床结果和技术转让交易。
科斯达克指数因机构抛售下跌2.41%至1084点。阿尔特奥根、佩普特龙和凯尔根等生技股上涨,机器人股在美国半导体下跌后暴跌。
韩国综合股价指数上涨2.25%至8228.70点,受半导体股推动,SK海力士飙升9.31%,三星电子上涨2.68%,而KOSDAQ下跌3.36%,市场呈现两极分化。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 ALTEOGEN Inc. 的业务、市场和增长信号的快速解答。
